Experts From Amazon Web Services and IDC Join Pyramid Executives on the Main Stage at SAPinsider 2022
The Chief Technology Officer and Senior Vice President of Strategic Alliances from Pyramid Analytics (Pyramid), a pioneering decision intelligence platform provider, will deliver main stage presentations with Chandana Gopal, Research Director, Future of Intelligence, IDC and Cristina Martin Greysman, WW Head of SAP on AWS Partner & Alliance Strategy at Amazon Web Services, at SAPinsider 2022, July 19 – 21 in Las Vegas.
Key Points:
- Avi Perez, Chief Technology Officer, Pyramid Analytics and Chandana Gopal, Research Director, Future of Intelligence, IDC will discuss what’s possible in their session, “Decision Intelligence: What’s Next in Data and Analytics for SAP BW and HANA.”
- Dave Henry, Senior Vice President of Strategic Alliances, Pyramid and Cristina Martin Greysman, WW Head of SAP on AWS Partner & Alliance Strategy at Amazon Web Services, will present “The ‘Beyond ERP’ Challenge: Maximizing the Use of SAP with Your Company’s Data Lake.”
- Join us at Booth 1245 on the SAPinsider 2022 exhibition floor for demos and presentations about creating additional value in SAP environments with decision intelligence.
- Come to SAPinsider 2022 in Las Vegas. Register with our discount code: PYRAMIDVIP.
The Pyramid Decision Intelligence Platform is the strongest analytics solution to run on SAP. The Pyramid Platform provides direct access. This eliminates the need to extract data out of SAP, protecting deep investment in SAP-driven business logic and security infrastructure. SAP data can also be blended with different data sources no matter where they reside to create a single view of a business and deliver reliable, consistent analytics.
Learn to Extract Maximum Value from SAP BW and HANA with Decision Intelligence
- Day 1: Tuesday, July 19. 11:30 a.m. – 12:20 p.m.
Decision Intelligence: What’s Next in Data and Analytics for SAP BW and HANA
Presenters: Avi Perez, Chief Technology Officer, Pyramid Analytics and Chandana Gopal, Research Director, Future of Intelligence, IDC.
Abstract: Many organizations that have invested in SAP BW and HANA are struggling to get insights from their data quickly without having to move it out of SAP. A key technology trend for 2022, Decision Intelligence, is what's next in analytics for SAP BW and HANA. It enables organizations to more quickly gain insights needed to make decisions, act faster, capitalize on opportunities and drive innovation. Imagine having the ability to scale for any data, any person, and any analytics need from the simple to the sophisticated. In this session, we'll talk about the barriers to getting insights from SAP, new technology developments in data and analytics, and share examples of companies who have elevated their analytics game on SAP.
- Day 2: Wednesday, July 20. 11 a.m. – 11:50 a.m.
The “Beyond ERP” Challenge:
Maximizing the Use of SAP with Your Company’s Data Lake
Presenters:
Cristina Martin Greysman, WW Head of SAP on AWS Partner & Alliance Strategy and Dave Henry, Senior Vice President of Strategic Alliances, Pyramid
Abstract: The adoption of data lakes is well underway. This includes how customers get more from their SAP investments using data lakes. However, deploying data lakes while integrating SAP systems can be daunting as customers get used to how it all comes together. Yet the use cases which combine data from SAP and data lakes are compelling. Through the lens of a customer case study, this session examines the business drivers for using data lakes with SAP. We introduce an agile approach to accessing, analyzing, and blending diverse data sets that insulates end-users from the underlying data architecture while ensuring security and strengthening IT governance.
There’s More! Attend Two Pyramid Impact20 Sessions
- Take Your SAP Investment to the Next Level with Pyramid Analytics with Kevin Kratzer, Solutions Engineer, Pyramid Analytics. Tuesday, July 19. 3:30 p.m. – 3:50 p.m.
- I Have Data Outside SAP—How Can I Get a Complete View of My Business Without Moving All My Data Around? with Matt Chapin, Solutions Engineer, Pyramid Analytics. Tuesday, July 19. 4:00 p.m. – 4:20 p.m.
Decision Intelligence is the Next Big Data Analytics Innovation
The next major innovation in analytics is Artificial Intelligence (AI). Applying AI across Data Prep, Business Analytics, and Data Science is what separates Decision Intelligence from traditional business intelligence tools such as Microsoft Power BI, Qlik, and Tableau. AI lowers the skills barrier by automating the highly technical work needed to prepare and analyze data and create and share reports and dashboards.
The Pyramid Decision Intelligence Platform delivers data-driven insights for anyone to make faster, more intelligent decisions. The Pyramid Platform provides instant access to any data, enables automated governed self-service for any person, and serves any analytics need, from the simple to the sophisticated. By uniquely combining Data Prep, Business Analytics, and Data Science with AI guidance in a single environment, the Pyramid Platform reduces cost and complexity while accelerating growth and innovation. This enables a strategic, organization-wide approach to Business Intelligence and Analytics.
About Pyramid Analytics
Pyramid is what’s next in analytics. Our unified decision intelligence platform delivers insights for anyone to make faster, more intelligent decisions. The Pyramid Decision Intelligence Platform provides direct access to any data, enables governed self-service for any person, and serves any analytics need in a no-code environment. The Pyramid Platform uniquely combines Data Prep, Business Analytics, and Data Science in a single environment with AI guidance, reducing cost and complexity while accelerating growth and innovation. The Pyramid Platform enables a strategic, organization-wide approach to Business Intelligence and Analytics, from the simple to the sophisticated. Schedule a demo.
Pyramid Analytics is incorporated in Amsterdam and has regional headquarters in global innovation and business centers, including London, New York City, and Tel-Aviv. Our team lives worldwide because geography should not be a barrier to talent and opportunity. Investors include H.I.G. Growth Partners, Jerusalem Venture Partners (JVP), Sequoia Capital, and Viola Growth. Learn more at Pyramid Analytics.
To view this piece of content from cts.businesswire.com, please give your consent at the top of this page.
View source version on businesswire.com: https://www.businesswire.com/news/home/20220714005012/en/
Contact information
UK
Susie Evershed
Resonance
+44 7966 145092
pyramidanalytics@resonancecrowd.com
US
Heather Racicot
Resonance
+1 360-632-5616
pyramidanalytics@resonancecrowd.com
Chas Kielt
Vice President of Global Corporate Communications, Pyramid Analytics
617.687.3371
chas.kielt@pyramidanalytics.com
About Business Wire
For more than 50 years, Business Wire has been the global leader in press release distribution and regulatory disclosure.
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
Takeda’s Zasocitinib Landmark Phase 3 Plaque Psoriasis Data Show Promise to Deliver Clear Skin in a Once-Daily Pill, Catalyzing a New Era of Treatment18.12.2025 10:00:00 EET | Press release
Takeda(TSE:4502/NYSE:TAK)today announced positive topline results for the two pivotal Phase 3randomized, multicenter, double-blind, placebo- and active comparator-controlled studies of zasocitinib (TAK-279), a next-generation, highly selective oral tyrosine kinase 2 (TYK2) inhibitor, in adults with moderate-to-severe plaque psoriasis (PsO). The studies demonstrated superiority of zasocitinib compared to placebo for the co-primary endpoints, static Physician Global Assessment (sPGA) 0/1 and Psoriasis Area and Severity Index (PASI) 75, at week 16, with a significantly greater PASI 75 response rate seen as early as week 4 and continuing to increase through week 24. The studies also met all 44 ranked secondary endpoints, including PASI 90, PASI 100 and sPGA 0 against placebo and apremilast, showing the potential of a convenient once-daily pill to deliver complete skin clearance for patients with PsO. “People living with psoriasis continue to seek safe, effective and fast-acting oral therap
DATROWAY ® Type II Variation Application Validated in the EU as First-Line Treatment for Patients with Metastatic Triple Negative Breast Cancer Who are Not Candidates for Immunotherapy18.12.2025 09:30:00 EET | Press release
The European Medicines Agency (EMA) has validated the Type II Variation marketing authorization application for DATROWAY® (datopotamab deruxtecan) as monotherapy for the first-line treatment of adult patients with unresectable or metastatic triple negative breast cancer (TNBC) who are not candidates for PD-1/PD-L1 inhibitor therapy. DATROWAY is a specifically engineered TROP2 directed DXd antibody drug conjugate (ADC) discovered by Daiichi Sankyo (TSE: 4568) and being jointly developed and commercialized by Daiichi Sankyo and AstraZeneca (LSE/STO/Nasdaq: AZN). The validation confirms the completion of the application and commences the scientific review process by the EMA’s Committee for Medicinal Products for Human Use. The application is based on data from the TROPION-Breast02 phase 3 trial presented in a late-breaking proffered paper session at the 2025 European Society for Medical Oncology (#ESMO25) Congress. In the trial, DATROWAY demonstrated statistically significant and clinical
Celltrion receives positive CHMP Opinion for SteQeyma™ (ustekinumab biosimilar) autoinjector18.12.2025 04:41:00 EET | Press release
Celltrion, Inc. today announced that the Committee for Medicinal Products for Human Use (CHMP) of the European Medicines Agency (EMA) has adopted a positive opinion of autoinjector of SteQeyma™, a biosimilar to Stelara® (ustekinumab), for the treatment of plaque psoriasis, psoriatic arthritis (PsA) and Crohn’s disease (CD). The positive CHMP opinion is for SteQeyma autoinjector in 45mg/0.5mL and 90mg/1mL, expanding the currently approved SteQeyma™ presentation, which includes 45mg/0.5mL, 90mg/1mL in a pre-filled syringe and 45mg/0.5mL in a vial for subcutaneous injection, as well as 130mg/26mL concentrate for solution for intravenous infusion. “The new SteQeyma™ autoinjector brings together convenience and practical usability to meet the everyday challenges faced by patients living with chronic inflammatory diseases. The full range of our SteQeyma™ dosage forms and strengths, with the autoinjector now added, provides patients and healthcare professionals with more individualized treatm
Megaport Expands into India, Accelerating Global Growth with Extreme IX Acquisition18.12.2025 03:15:00 EET | Press release
Megaport Limited (ASX: MP1) (“Megaport”), the world’s leading Network as a Service (NaaS) provider, today announced the acquisition of Extreme IX,India’s leading Internet Exchange operator, from Extreme Labs, a Bulgaria-headquartered software and network engineering company that incubated the Extreme IX platform. The acquisition expands Megaport’s global platform into one of the world’s fastest-growing digital infrastructure markets and supports the Company’s strategy to deliver scalable, high-performance connectivity services across APAC. The acquisition establishes Megaport’s presence across seven Internet Exchanges in major Indian metros: Delhi, Kolkata, Hyderabad, Chennai, Bengaluru, Mumbai, and Pune, connecting 40+ data centres and more than 400 customers. It also accelerates Megaport’s planned market entry by nearly three years, while adding a seasoned in-country team spanning operations, support, sales, finance, and leadership to enable rapid integration and future growth. The E
IonQ and QuantumBasel Expand Long-Term Partnership in Next-Generation Quantum Systems17.12.2025 23:10:00 EET | Press release
IonQ (NYSE: IONQ), the world’s leading quantum company, today announced an expanded agreement with QuantumBasel, the quantum initiative of uptownBasel, Switzerland’s innovation campus. The extended contract grants QuantumBasel ownership of its existing IonQ Forte Enterprise system and secures ownership of a next-generation Tempo system. This new agreement brings the total deal value of the QuantumBasel and IonQ partnership to over $60 million and extends IonQ’s on-site presence in Switzerland four more years, continuing through 2029. QuantumBasel is IonQ’s official Innovation Center in Europe, serving as a hub for European industry, academia, and research institutions to explore practical quantum computing applications and access IonQ’s latest enterprise-grade systems. “Our extended partnership with QuantumBasel represents a cornerstone of IonQ’s global strategy,” said Niccolo de Masi, Chairman and CEO of IonQ. “QuantumBasel continues to be a critical innovation node for our company as
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom
